PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Helps investors judge whether earnings growth is driven by sustainable operations or temporary factors. Consistent, organic income expansion can justify a higher intrinsic value for patient, long-term investors.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
88.49%
R&D growth 1.25-1.5x AXSM's 59.68%. Martin Whitman would scrutinize investment rationale.
34.89%
G&A growth less than half of AXSM's 99.21%. David Dodd would verify if efficiency advantage is structural.
No Data
No Data available this quarter, please select a different quarter.
77.92%
Other expenses change of 77.92% while AXSM maintains costs. Bruce Berkowitz would investigate efficiency.
59.22%
Operating expenses growth while AXSM reduces costs. John Neff would investigate differences.
59.22%
Total costs growth while AXSM reduces costs. John Neff would investigate differences.
No Data
No Data available this quarter, please select a different quarter.
77.92%
Similar D&A growth to AXSM's 84.15%. Walter Schloss would investigate industry patterns.
-37.27%
EBITDA decline while AXSM shows 0.00% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-59.22%
Both companies show declining income. Martin Whitman would check industry conditions.
No Data
No Data available this quarter, please select a different quarter.
-87.81%
Other expenses reduction while AXSM shows 229.40% growth. Joel Greenblatt would examine advantage.
-272.88%
Pre-tax income decline while AXSM shows 88.11% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-272.88%
Net income decline while AXSM shows 88.11% growth. Joel Greenblatt would examine position.
No Data
No Data available this quarter, please select a different quarter.
-252.38%
EPS decline while AXSM shows 92.63% growth. Joel Greenblatt would examine position.
-313.33%
Diluted EPS decline while AXSM shows 92.63% growth. Joel Greenblatt would examine position.
10.47%
Share count reduction exceeding 1.5x AXSM's 62.59%. David Dodd would verify capital allocation.
-20.54%
Diluted share reduction while AXSM shows 62.59% change. Joel Greenblatt would examine strategy.